The B16F10 tumor cells expressing OVA257-264-peptide (i.e., B16-MO5 cells) were s.c. injected into wild-type and SKAP55−/− recipient mice for 7 days; OVA257-264-pulsed DCs were then injected twice at day 7 and day 14 for therapy (Supplementary Fig S6A). This evidence concerns the gene SKAP1 and neoplasm.